Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
2021 · npj Precision Oncology · 28 citations
https://doi.org/10.1038/s41698-021-00220-0
S
Sorin Armeanu–Ebinger
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
73
Papers
1.2K
Citations
18
h-index
33
i10-index
Sorin Armeanu–Ebinger is an academic researcher from University Children's Hospital Tübingen. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer Genomics and Diagnostics & Sarcoma Diagnosis and Treatment. The author has an h-index of 18, co-authored 63 publications.
Papers by this author
worksUV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents
2023 · EBioMedicine · 13 citations
https://doi.org/10.1016/j.ebiom.2023.104797
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
2025 · The Lancet Oncology · 4 citations
https://doi.org/10.1016/s1470-2045(25)00097-x
Melanoma-specific survival and relapse-free survival are significantly improved for tumors with high tumor mutational burden and BRAF V600 mutation – results of 83 stage IIIC-IV patients with adjuvant anti-PD-1 therapy
2025 · EJC Skin Cancer · 0 citations
https://doi.org/10.1016/j.ejcskn.2025.100360
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat